allovir
announces
fda
clearance
investigational
new
drug
application
ind
treatment
patients
allogeneic
cell
therapy
candidate
designed
target
patients
clinical
trial
begin
cambridge
globe
newswire
allovir
nasdaq
alvr
late
cell
therapy
company
announced
food
drug
administration
fda
cleared
investigational
new
drug
application
ind
allogeneic
cell
therapy
candidate
designed
target
virus
causes
severe
viral
disease
developed
arrest
progression
eradicating
cells
continues
devastating
impact
patients
families
around
world
said
david
hallal
chairman
chief
executive
officer
allovir
increasing
body
evidence
important
role
cells
body
fight
allovir
together
colleagues
baylor
college
medicine
working
great
sense
urgency
leverage
highly
innovative
platform
advance
study
early
research
suggests
cells
play
important
role
body
fight
hospitalized
patients
lymphopenic
reduced
cell
counts
reductions
cell
counts
correlate
negatively
survival
reduced
cell
counts
observed
prevalent
older
patients
severe
illness
regardless
age
march
allovir
announced
expanded
research
collaboration
baylor
college
medicine
bcm
discover
develop
allogeneic
therapies
following
submission
ind
bcm
fda
notified
bcm
clinical
hold
due
questions
related
raw
materials
used
manufacturing
process
bcm
submitted
complete
response
questions
identified
clinical
hold
fda
removed
hold
allowing
clinical
study
start
allovir
allovir
leading
late
cell
therapy
company
focus
restoring
natural
immunity
viral
diseases
patients
severely
weakened
immune
systems
company
innovative
proprietary
technology
platforms
leverage
allogeneic
specific
cells
targeting
devastating
viruses
patients
cell
deficiencies
risk
consequences
viral
diseases
allovir
technology
manufacturing
process
enables
potential
treatment
prevention
spectrum
devastating
viruses
single
allogeneic
cell
therapy
company
advancing
multiple
clinical
trials
across
product
portfolio
information
visit
allovir
uses
website
means
disclosing
material
information
complying
disclosure
obligations
regulation
fd
disclosures
included
company
website
investors
media
section
accordingly
investors
monitor
portions
allovir
website
addition
following
press
releases
sec
filings
public
conference
calls
webcasts
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
amended
including
without
limitation
statements
regarding
allovir
development
regulatory
status
product
candidates
strategy
business
plans
focus
words
may
could
would
expect
plan
anticipate
intend
believe
estimate
predict
project
potential
continue
target
similar
expressions
intended
identify
statements
although
statements
contain
identifying
words
statements
press
release
based
management
current
expectations
beliefs
subject
number
risks
uncertainties
important
factors
may
cause
actual
events
results
differ
materially
expressed
implied
statements
contained
press
release
including
without
limitation
related
allovir
financial
results
timing
completion
allovir
clinical
trials
product
candidates
whether
allovir
product
candidates
receive
approval
food
drug
administration
fda
foreign
regulatory
authorities
competition
biopharmaceutical
companies
risks
identified
allovir
sec
filings
allovir
cautions
place
undue
reliance
statements
speak
date
made
allovir
disclaims
obligation
publicly
update
revise
statements
reflect
change
expectations
events
conditions
circumstances
statements
may
based
may
affect
likelihood
actual
results
differ
set
forth
statements
statements
contained
press
release
represent
allovir
views
date
hereof
relied
upon
representing
views
subsequent
date
media
contact
courtney
heath
scientpr
investor
contact
medha
chadha
allovir
ir
